[Role of the lipid formulation of amphotericin B in pediatric oncohematology].
Leverger
G
G
Service d'Onco-Hématologie, Hôpital Trousseau, Paris.
D000666:Amphotericin B / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D002648:Child; D004338:Drug Combinations; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007938:Leukemia / Q000150:complications*; D009181:Mycoses / Q000188:drug therapy* / Q000209:etiology; D009196:Myeloproliferative Disorders / Q000150:complications*; D010713:Phosphatidylcholines / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D010715:Phosphatidylglycerols / Q000008:administration & dosage* / Q000493:pharmacokinetics*
D004338:Drug Combinations; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D000666:Amphotericin B